| Indicator | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥132.0B | ¥119.3B | +10.6% |
| Operating Income / Operating Profit | ¥8.4B | ¥6.2B | +35.4% |
| Ordinary Income | ¥7.8B | ¥4.4B | +79.3% |
| Net Income / Net Profit | ¥3.5B | ¥-1.5B | +329.2% |
| ROE | 1.1% | -0.5% | - |
FY2026 Q1 results: Revenue ¥132.0B (vs ¥119.3B prior year, +¥12.6B +10.6%), Operating Income ¥8.4B (vs ¥6.2B, +¥2.2B +35.4%), Ordinary Income ¥7.8B (vs ¥4.4B, +¥3.4B +79.3%), Quarterly net loss attributable to owners of parent ¥0.3B (prior year net loss ¥5.1B). A clear trend of revenue and profit growth emerged, with Operating Margin improving to 6.3% from 5.2% in the prior year (+1.1pt). Although net income attributable to owners of parent improved by ¥4.8B year-on-year, high tax burden (effective tax rate 54.7%) and allocation of profit to non-controlling interests of ¥3.9B resulted in continued loss. The results are characterized by improved profitability at the operating stage and a large increase in ordinary income.
[Revenue] Revenue reached ¥132.0B (+10.6% YoY), achieving double-digit growth. The core HealthCare segment drove performance with ¥121.9B (+11.6%), accounting for 92.3% of total. By channel, direct sales were ¥87.1B (+5.2%) and remained solid, while OEM / Raw Materials / Overseas grew substantially to ¥25.0B (+52.0%). Distribution was ¥9.7B (-0.5%) and flat. Growth in OEM / Raw Materials contributed to mix improvement; Biofuel was ¥2.6B (+1.6%) and Others ¥7.6B (-0.9%), remaining small.
[Profitability] Operating Income was ¥8.4B (+35.4% YoY), outpacing revenue growth. Gross Profit was ¥89.9B (Gross Margin 68.1%), up ¥6.6B YoY, but Gross Margin declined 1.7pt from 69.8% the prior year. SG&A was ¥81.5B (SG&A ratio 61.8%), up ¥4.4B YoY, but SG&A ratio improved 2.9pt from 64.7% the prior year, offsetting the gross margin decline and expanding operating-stage margins. Ordinary Income was ¥7.8B (+79.3%), growing more than Operating Income, aided by an increase in interest income of ¥0.4B and limited FX losses of ¥0.8B. Special losses of ¥2.6B (business restructuring costs) were recorded, leaving Profit Before Tax ¥7.8B. Corporate taxes of ¥4.3B (effective tax rate 54.7%) and net income attributable to non-controlling interests of ¥3.9B were deducted, resulting in a quarterly net loss attributable to owners of parent of ¥0.3B. The prior year net loss was ¥5.1B, so the loss narrowed significantly but did not return to profit. In conclusion, while revenue and operating profit growth are established, high tax burden and allocation to non-controlling interests continue to compress final earnings quality.
The HealthCare segment posted Revenue ¥121.9B (+11.6%), Operating Income ¥15.0B (+24.6%), and Operating Margin 12.3%, maintaining high profitability as the core business. Operating Income improved from ¥12.0B and margin from 11.0% in the prior year, driven by scale effects and SG&A efficiency. The Biofuel segment recorded Revenue ¥2.6B (+1.6%), Operating Loss ¥1.3B (prior year loss ¥0.5B), and margin -51.6%, widening its deficit. The Others segment had Revenue ¥7.6B (-0.9%), Operating Loss ¥1.1B (prior year loss ¥1.0B), and margin -14.2%, remaining in loss. After eliminating inter-segment sales and allocating corporate expenses of ¥4.2B (prior year ¥4.4B), consolidated Operating Income was ¥8.4B. HealthCare’s high profitability supports group profits, while ongoing losses in Biofuel and Others remain structural issues.
[Profitability] Operating Margin 6.3% (up +1.1pt from 5.2% prior year), Net Margin 2.7% (improved from negative), ROE 1.1% remained low. Gross Margin 68.1% declined 1.7pt from 69.8%, but SG&A ratio improved to 61.8% (down -2.9pt from 64.7%), expanding operating-stage margins. [Cash Quality] Interest Coverage 5.5x (Operating Income ¥8.4B ÷ Interest Expense ¥1.5B), indicating minimum interest payment capacity. Working capital efficiency is prolonged: DSO 148 days (Accounts Receivable ¥53.6B ÷ Revenue ¥132.0B × 365), DIO 378 days (Inventory ¥25.0B ÷ Cost of Goods Sold ¥42.0B × 365), CCC 341 days, highlighting delays in cash conversion. [Investment Efficiency] ROIC 1.9% (Operating Income ¥8.4B × (1-0.547) ÷ Invested Capital ¥200.1B; Invested Capital = Net Assets ¥308.0B - Cash & Deposits ¥188.7B + Interest-bearing Debt ¥216.2B - Contract Liabilities ¥13.6B, simplified calculation), indicating low capital efficiency with significant room for improvement. [Financial Soundness] Equity Ratio 43.6% (up +4.2pt from 39.4% prior year), Current Ratio 117.0% (Current Assets ¥322.2B ÷ Current Liabilities ¥275.4B), Quick Ratio 107.9%, providing minimal short-term liquidity. D/E Ratio 1.29x (Interest-bearing Debt ¥216.2B ÷ Equity ¥167.1B; Equity = Net Assets ¥308.0B - Share Subscription Rights ¥0.5B - Non-controlling Interests -¥20.4B - Valuation and Translation Adjustments ¥9.0B), Debt/Capital Ratio 41.2% indicating neutral leverage. However, short-term borrowings surged to ¥192.8B and short-term liabilities ratio is 89%, raising refinancing risk. Intangible Asset Ratio 43.0% (Intangible Assets ¥303.8B ÷ Total Assets ¥706.6B) and Goodwill Ratio 15.5% (Goodwill ¥109.2B ÷ Total Assets ¥706.6B) indicate high asset intangibility and sensitivity to future impairment risk.
Detailed disclosure of Operating Cash Flow is not available, but recording Operating Income ¥8.4B supports earnings quality. Conversely, prolonged working capital is notable—DSO 148 days, DIO 378 days, CCC 341 days—likely deteriorating from prior year, indicating accounting profit is not easily converting to cash. Balance sheet trends show Cash & Deposits decreased to ¥188.7B (from ¥211.6B prior year, -¥22.9B), while Short-term Borrowings surged to ¥192.8B (from ¥39.4B, +¥153.4B), suggesting reliance on short-term borrowing to fund working capital. Long-term Borrowings decreased to ¥23.4B (from ¥179.2B, -¥155.8B), shifting interest-bearing debt structure toward short-term. Interest payments increased to ¥1.5B (from ¥1.2B, +¥0.3B), and rising interest burden from increased short-term borrowings becomes a headwind to cash flow. Contract Liabilities ¥13.6B (advance receipts) were flat vs ¥13.7B prior year and, while some prepayment structure exists, it has not improved working capital. To generate free cash flow, urgent inventory reduction (shorten DIO) and accelerated receivables collection (shorten DSO) are required.
Core recurring earnings are based on Operating Income ¥8.4B, supported by high margins in the HealthCare segment. Non-operating income ¥1.5B consisted of Interest Income ¥0.4B, Equity in Earnings of Affiliates ¥0.1B, Subsidy Income ¥0.8B, and Other ¥0.2B; excluding subsidies, non-operating income / revenue ratio is limited at approximately 0.5%. Non-operating expenses ¥2.1B were primarily Interest Expense ¥1.5B, FX Loss ¥0.8B, and Fees ¥0.3B, centered on financial costs. Ordinary Income ¥7.8B showed only a small decrease from Operating Income, maintaining an operating-led earnings structure. Special losses ¥2.6B were business restructuring costs, a one-time factor. Corporate taxes ¥4.3B on Profit Before Tax ¥7.8B resulted in an effective tax rate of 54.7%, a high level, possibly influenced by recognition of tax effects or constraints on deferred tax assets. Net income attributable to non-controlling interests ¥3.9B heavily pressured final earnings, resulting in a quarterly net loss attributable to owners of parent of ¥0.3B. Comprehensive income was ¥5.3B (including Foreign Currency Translation Adjustments ¥1.6B and Remeasurements of Defined Benefit Plans ¥0.1B), ¥1.8B higher than Net Income ¥3.5B, so Other Comprehensive Income provided some financial cushion. Operating and ordinary margins are well linked and earnings quality is rooted in operating activities, but tax burden and NCI allocation at the final stage substantially dilute earnings attributable to owners of parent. From an accrual perspective, prolonged working capital widens the gap between accounting profit and cash flow, leaving room to improve cash realization of profits.
Full Year / FY guidance: Revenue ¥520.0B (vs prior year +3.2%), Operating Income ¥32.0B (+2.5%), Ordinary Income ¥28.0B (+18.4%), Dividend forecast ¥0. Q1 progress rates: Revenue 25.4% (¥132.0B ÷ ¥520.0B), Operating Income 26.2% (¥8.4B ÷ ¥32.0B), Ordinary Income 27.9% (¥7.8B ÷ ¥28.0B), exceeding a standard 25% pace. There are no revisions to the FY forecast or dividend forecast in Q1; the initial plan remains unchanged. If HealthCare continues to grow and SG&A efficiency persists, the probability of achieving the full-year target is high. However, expanding losses in Biofuel and Others and increased interest burden from short-term borrowings are downside risks. Net income attributable to owners of parent remained in loss in Q1; the full-year movement in tax burden and NCI allocation will determine final earnings attainment.
Dividend forecast is ¥0 this period (same as prior fiscal year), maintaining no dividend policy. Given the quarterly net loss attributable to owners of parent ¥0.3B, continued final-stage losses, and priority on securing funding stability with a short-term liabilities ratio of 89%, the hurdle to resume dividends is high. Retained earnings improved to ¥4.8B (from -¥30.7B prior year, improvement ¥35.5B), significantly reducing accumulated deficit, but the absolute amount remains small and distributable profit is limited. No share buyback disclosure; shareholder returns are expected to be deferred for the time being. Strengthening the balance sheet through internal reserves and eliminating losses in Biofuel and Others are prerequisites for resuming dividends.
Refinancing Risk: Short-term borrowings surged to ¥192.8B (from ¥39.4B, +¥153.4B, +389.5%), and the short-term liabilities ratio reached 89%. Compared with Cash & Deposits ¥188.7B, the Cash / Short-term Liabilities ratio is 0.98x, indicating tightness and concentrated maturities risk. In a rising interest rate environment, interest burden could increase and rollover may become difficult, potentially leading to liquidity stress.
Intangible Asset Impairment Risk: Intangible Assets ¥303.8B (43.0% of Total Assets) and Goodwill ¥109.2B (35.5% of Net Assets) indicate extremely high dependence on intangibles. If HealthCare earnings fall short of plans or the profitability of businesses to which goodwill is allocated deteriorates, impairment losses may occur and materially erode net assets.
Deterioration of Working Capital Efficiency: DSO 148 days, DIO 378 days, CCC 341 days indicate pronounced prolongation and delayed cash generation relative to revenue growth. Continued slowdown in inventory turnover or extended receivables collection could increase working capital needs and further deepen reliance on short-term borrowings.
Profitability & Return
| Indicator | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 6.3% | – | – |
| Net Margin | 2.7% | – | – |
While industry data is limited for relative evaluation, the company secures a certain level of profitability underpinned by a high Gross Margin of 68.1%.
Growth & Capital Efficiency
| Indicator | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 10.6% | – | – |
Revenue growth of 10.6% represents double-digit expansion, driven by the HealthCare segment.
※Source: Company compilation
If HealthCare’s high profitability (Operating Margin 12.3%) and SG&A efficiency-driven Operating Margin improvement (YoY +1.1pt) are sustainable, there is upside to the full-year results. Conversely, the downward trend in Gross Margin (-1.7pt) suggests mix shifts or rising raw material costs, and maintaining gross margins will be key to future profitability.
The sharp increase in Short-term Borrowings (+¥153.4B) and Short-term Liabilities Ratio of 89% indicate shortening cash cycles and refinancing dependence. Improving working capital efficiency (shortening DSO, DIO, CCC) to enhance cash generation is a prerequisite for financial stability; quarterly trends in working capital and short-term borrowings will be focal points.
Final earnings attributable to owners of parent remained in loss due to tax burden (effective tax rate 54.7%) and NCI allocation (¥3.9B). As long as the substantial increase in Ordinary Income is diluted at the final stage, resuming dividends and shareholder returns will be difficult; normalization of tax effects and stabilization of NCI allocation are prerequisites for enhancing shareholder value.
This report was automatically generated by AI analyzing XBRL financial statement data and is a financial analysis document. It does not constitute a recommendation to invest in any particular security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed financial data. Investment decisions are your responsibility; please consult professional advisors as necessary.